The government has promised a ‘Dementia Moonshot’ to double dementia research funding. Laura Mullaney, Public Affairs Officer, looks at how this should be invested.
The government has promised a ‘Dementia Moonshot’ to double dementia research funding. Laura Mullaney, Public Affairs Officer, looks at how this should be invested.
...
Researchers presented results from a phase 3 trial of pimavanserin that showed a significant reduction in the risk of relapse into psychosis compared to the placebo.
Biogen presented their results on Aducanumab, their newest drug for the treatment of Alzheimer's disease at the CTAD conference 2019 in San Diego, USA.
Two new papers are being published in Science Translational Medicine which shed more light on the mechanism that leads to cognitive ageing in mice and humans.
Biogen Inc. will ask U.S. drug regulators to approve the company’s experimental Alzheimer’s therapy, reviving the nearly abandoned treatment, after a new analysis of data from two failed clinical trials showed promising results.
Have you ever looked at research findings and thought, ‘I could have told you that’? Nicola Hart, in our Research Translation team, explains why this kind of knowledge is vital.
Have you ever looked at research findings and thought, ‘I could have told you that’? Nicola Hart, in our Research Translation team, explains why this kind of knowledge is vital.
...
Today, Axon Neuroscience has announced the results of the Phase II trial for AADvac1, its first-in-class vaccine aimed at slowing down the progression of Alzheimer’s Disease
Scientists have visualised for the first time protein ‘tangles’ associated with dementia in the brains of patients who have suffered a single head injury
Dementia Support Line